FDA cleared Wello offers an FDA Class II non-contact medical device powered by WelloAI that detects potential infections before symptoms, presenting a proactive healthcare solution ideal for workplaces seeking infection control and reduced absenteeism.

Strategic partnerships Recent collaborations with Lotus Biosecurity and Canon Solutions America indicate a track record of channel partnerships and enterprise deployments, suggesting sales opportunities through system integrators and large distributors.

B2B workplace focus Target markets include workplaces and communities aiming to minimize infection risks; prioritize selling to facilities with high footfall or captive populations such as clinics, offices, campuses, and industrial sites.

Growth signals Revenue range and acquisition activity (Maple acquisition in 2021) imply a growth trajectory and potential for larger deals, including multi-site deployments and managed service arrangements.

Tech ecosystem Existing digital marketing and analytics tools (Google Ads, Facebook Pixel, AdRoll) and a scalable AI platform offer opportunities to leverage data-driven campaigns, co-marketing, and case studies to accelerate enterprise adoption.